Arcturus Therapeutics (NASDAQ:ARCT) Issues Quarterly Earnings Results

Arcturus Therapeutics (NASDAQ:ARCT) announced its earnings results on Thursday. The biotechnology company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.43, FiscalAI reports. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. The firm had revenue of $18.30 million for the quarter, compared to analyst estimates of $8.00 million.

Here are the key takeaways from Arcturus Therapeutics’ conference call:

• ARCT-2601 advances with a new delivery platform: Arcturus reported 38-fold greater potency for LUNAR 2.0 than its earlier formulation in non-human primates and plans to start a Phase II study in Q1 2027, enrolling up to six patients. Top-line data are expected in the second half of 2027, though the clinical benefit of the delivery improvement remains unproven.
• CF program progresses, with safety encouraging but efficacy still pending: The company expects to complete enrollment of up to 20 patients receiving ARCT-032 by year-end and present full Phase II data in Q2 2027. It reported no significant safety events to date and said some patients completed 12 weeks of treatment; the timing of a go/no-go decision remains unspecified, and efficacy data have not yet been reported.
• Cash runway extends through year-end 2028: Arcturus reported $184.8 million in cash and equivalents at September 30 and said it expects its resources to fund operations for more than two years.
• Nine-month net loss widened: Net loss was $58.2 million for the first nine months of 2026, versus $36.7 million a year earlier, while revenue fell to $23.3 million from $74.8 million, primarily reflecting the prior-year CSL collaboration revenue and lower BARDA grant revenue.
• Arcturus regained KOSTAIVE marketing rights in Europe and the U.K.: The company said the transfer from CSL Seqirus supports potential commercial activities in those markets in 2027; it plans to seek a U.S. commercial partner, while Meiji continues commercialization in Japan.

Arcturus Therapeutics Price Performance

Shares of ARCT opened at $10.35 on Friday. The stock has a market cap of $294.15 million, a PE ratio of -3.36 and a beta of 2.62. Arcturus Therapeutics has a 12 month low of $5.50 and a 12 month high of $17.96. The stock’s 50-day moving average is $13.10 and its two-hundred day moving average is $9.05.

Analysts Set New Price Targets

ARCT has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Thursday, October 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Thursday, September 24th. Zacks Research upgraded shares of Arcturus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 21st. Roth Capital reiterated a “buy” rating and set a $41.00 price objective on shares of Arcturus Therapeutics in a report on Wednesday, September 2nd. Finally, BTIG Research lowered their target price on Arcturus Therapeutics from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Arcturus Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $22.29.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a biotechnology company headquartered in San Diego, California, focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company’s platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acids into cells, as well as technologies for producing and administering mRNA and self-amplifying RNA.

The company’s development programs address infectious diseases and rare genetic disorders. Arcturus has developed KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine known as ARCT-154, in collaboration with CSL.